2-氨基-4-苯基氨基-6-甲基嘧啶 | 7781-29-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-4-苯基氨基-6-甲基嘧啶
• 英文名称: 6-methyl-4-phenylaminopyrimidin-2-amine
• 英文别名: 2-amino-4-anilino-6-methylpyrimidine；UTSAM477；6-methyl-N⁴-phenyl-pyrimidine-2,4-diamine；6-methyl-N⁴-phenyl-pyrimidine-2,4-diyldiamine；6-Methyl-N⁴-phenyl-pyrimidin-2,4-diyldiamin；2-Amino-4-anilino-6-methyl-pyrimidin；2-Amino-4-phenylamino-6-methylpyrimidine；6-methyl-4-N-phenylpyrimidine-2,4-diamine
• CAS: 7781-29-5
• 化学式: C₁₁H₁₂N₄
• mdl: MFCD00814051
• 分子量: 200.243
• InChiKey: FHBLLCUQBZVVMP-UHFFFAOYSA-N

物化性质

• 熔点：
  170-172 °C
• 沸点：
  441.0±37.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-4-苯基氨基-6-甲基嘧啶 在 溴 、 sodium acetate 、 溶剂黄146 作用下， 生成 5-Brom-2-amino-6-<4-brom-anilino>-4-methyl-pyrimidin
  参考文献：
  名称：

  Bromination of Some Anilinopyrimidines

  摘要：

  DOI：

  10.1021/ja01135a063
• 作为产物：
  描述：

  2,4-二氯-6-甲基嘧啶 在 乙醇 、 氨 作用下， 生成 2-氨基-4-苯基氨基-6-甲基嘧啶
  参考文献：
  名称：

  Gabriel; Colman, Chemische Berichte, 1899, vol. 32, p. 2934

  摘要：

  DOI：

文献信息

• Structure-based design, synthesis and evaluation of 2,4-diaminopyrimidine derivatives as novel caspase-1 inhibitors
  作者：Shivani Patel、Palmi Modi、Vishal Ranjan、Mahesh Chhabria

  DOI：10.1016/j.bioorg.2018.03.019

  日期：2018.8

  caspase-1 may provide a potential therapeutic strategy for the treatment of chronic inflammatory diseases. Here we have reported structure-based design, synthesis and biological evaluation of 2,4-diaminopyrimidine derivatives (6a-6w) as potential caspase-1 inhibitors. Six compounds 6m, 6n, 6o, 6p, 6q and 6r showed significant enzymatic inhibition with IC50 ranging from 0.022 to 0.078 µM. These compounds

  白介素-1β转化酶通过使促炎性细胞因子IL-1β，IL-18和IL-33成熟，从而导致多种炎症和自身免疫性疾病。因此，抑制caspase-1可能为慢性炎性疾病的治疗提供潜在的治疗策略。在这里，我们已经报告了作为潜在caspase-1抑制剂的2,4-二氨基嘧啶衍生物（6a-6w）的基于结构的设计，合成和生物学评估。六种化合物6m，6n，6o，6p，6q和6r对IC 5 0表现出明显的酶抑制作用范围为0.022至0.078 µM。这些化合物在亚微摩尔浓度下也显示出优异的细胞效价。此外，分子对接研究提供了对caspase-1抑制特异的有用的结合见解。所有这些结果表明，化合物6m，6n和6o可能是开发新型caspase-1抑制剂作为抗炎药的潜在原因。
• The Effects of Membership in Church-Related Associations and Labor Unions on Age Differences in Voluntary Association Affiliations
  作者：Jon Hendricks、Stephen J. Cutler

  DOI：10.1093/geront/41.2.250

  日期：2001.4.1

  Purpose:When compositional differences between age groups are controlled, the bivariate, curvilinear pattern of age differences in voluntary association memberships is replaced by one in which peak membership levels occur in late middle age and remain relatively stable thereafter. We sought to determine if this adjusted pattern persists when widespread memberships in two types of associations are removed: (1) church-related organizations, in which membership increases with age but may be confounded with church membership per se; and (2) labor unions, in which membership is also widespread but may not be "voluntary."Design and Methods:Total memberships in 14 types of associations were examined using aggregated data from 12 national surveys conducted between 1974 and 1994.Results:The familiar curvilinear relationship at the bivariate level appears, but in the multivariate analysis, membership levels rise from ages 18–24 through 55–59 and persist close to that level through ages 85 and older.Implications:The results reaffirm that age differences in voluntary association affiliations are due to age-based compositional differences; they also show, however, that the pattern observed with controls is neither driven by membership in church-related "associations" nor altered when membership in labor unions is excluded.

  目的：当年龄组之间的构成差异受到控制时，自愿协会会员资格中年龄差异的二元曲线模式将被一种会员水平峰值出现在中年后期并在此后保持相对稳定的模式所取代。我们试图确定当两类协会的广泛会员资格被取消时，这种调整后的模式是否仍然存在：（1）与教会相关的组织，其中会员资格随着年龄的增长而增加，但可能与教会会员资格本身相混淆； (2) 工会，其成员资格也很广泛，但可能不是“自愿的”。 设计和方法：使用 1974 年至 1994 年间进行的 12 次全国性调查的汇总数据对 14 类协会的总成员资格进行了审查。双变量水平上出现了熟悉的曲线关系，但在多变量分析中，会员水平从 18-24 岁上升到 55-59 岁，并在 85 岁及以上一直保持接近该水平。 意义：结果再次证实，自愿协会中的年龄差异隶属关系是由于年龄构成差异造成的；然而，它们也表明，通过控制观察到的模式既不是由与教会有关的"协会"的成员资格所驱动的，也不是因为工会成员资格被排除在外而改变的。
• Pyrimidine derivatives
  申请人：Imperial Chemical Industries Plc

  公开号：US05223505A1

  公开（公告）日：1993-06-29

  This invention concerns novel aminopyrimidinium salts of the formula I: ##STR1## in which R.sup.1 is alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl or cycloalkyl-alkyl; one of R.sup.2 and R.sup.6 is a basic group selected from amino, alkylamino, dialkylamino of up to eight carbon atoms, pyrrolidino, piperidino and morpholino; and the other of R.sup.2 and R.sup.6 is hydrogen, alkyl, alkenyl, alkoxyalkyl, phenyl, phenylalkyl, cycloalkyl or cycloalkyl-alkyl; or both of R.sup.2 and R.sup.6 are basic groups as mentioned above; and R.sup.5 is hydrogen, (1-4C)alkyl or (3-6C)alkenyl; or R.sup.2 is a basic group as mentioned above, and R.sup.5 and R.sup.6 together form alkylene or, together with the appendant carbon atoms of the pyrimidine ring, complete a benzene ring; R.sup.4 is hydrogen, alkyl, cycloalkyl-alkyl, alkenyl, alkynyl or phenylalkyl; or R.sup.4 is an optionally substitutued alkylene or alkenylene linked to the nitrogen atom of the group Q.A.N--, either of which linking groups may thereby completing a ring including two adjacent carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen atom of the group --A.N--; A is a direct bond to the the group --N(R.sup.4)-- or is alkylene or oxyalkylene; Q is a pyridyl, furyl, thienyl or phenyl moiety; and Y is a physiologically acceptable anion; but excluding a number of compounds specified hereinafter. The invention also includes certain closely related anhydro-base derivatives which, like the formula I compounds, possess beneficial effects on the cardiovascular system (and in particular beneficial effects modulated via the sino-atrial node). Also included are pharmaceutical compositions containing the formula I compound (or a related anhydro-base) as active ingredient, and processes for the manufacture of the various novel compounds.

  本发明涉及公式I的新型氨基嘧啶盐：##STR1## 其中R.sup.1是烷基，烯基，环烷基，苯基，苯基烷基或环烷基-烷基; R.sup.2和R.sup.6中的一个是从氨基，碳数不超过八个的烷基氨基，二烷基氨基，吡咯烷基，哌啶基和吗啉中选择的碱性基团; 另一个是氢，烷基，烯基，烷氧基烷基，苯基，苯基烷基，环烷基或环烷基-烷基; 或者R.sup.2和R.sup.6都是上述的碱性基团; R.sup.5是氢，(1-4C)烷基或(3-6C)烯基; 或者R.sup.2是上述的碱性基团，而R.sup.5和R.sup.6共同形成烷基ene或与嘧啶环的附加碳原子一起形成苯环; R.sup.4是氢，烷基，环烷基-烷基，烯基，炔基或苯基烷基; 或者R.sup.4是可选取代的烷基ene或烯基ene，连接到Q.A.N-的氮原子，其中任何一个连接基团可以包括Q的相邻碳原子之一和相邻氮原子的碳原子，A的碳原子和-A.N-基团的相邻氮原子，从而形成一个环; A是直接键到-N(R.sup.4)-基团的键合或烷基ene或氧烷基ene; Q是吡啶基，呋喃基，噻吩基或苯基基团; Y是生理上可接受的阴离子; 但不包括下面指定的一些化合物。本发明还包括某些密切相关的无水基衍生物，像公式I化合物一样，在心血管系统上具有有益的作用(特别是通过窦房结调节的有益作用)。还包括含有公式I化合物(或相关的无水基)作为活性成分的制药组合物，以及制造各种新型化合物的过程。
• Compounds and methods of use to treat infectious diseases
  申请人：Bukrinsky I. Michael

  公开号：US20060014760A1

  公开（公告）日：2006-01-19

  The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.

  本发明涉及具有抗感染活性的烷基芳基羰基化合物。该发明的化合物可用于靶向特定的核定位信号，从而阻止特定蛋白质或分子复合物进入细胞核。本发明包括使用这些化合物治疗或预防传染病的方法，如寄生虫和病毒性疾病，包括例如疟疾和获得性免疫缺陷综合症。本发明还教授了使用这些化合物检测核定位序列中存在的某些特定蛋白质结构的方法。
• Compounds for treating infectious diseases
  申请人：The Picower Institute for Medical Research

  公开号：US05840893A1

  公开（公告）日：1998-11-24

  There is disclosed compound according to the formula: ##STR1## wherein A, independently,=CH.sub.3 or CH.sub.2 CH.sub.3, P=1 or 2; and ##STR2## wherein X=NH.sub.2, CH.sub.3 or CH.sub.2 CH.sub.3 ; X'=CH.sub.3 or CH.sub.2 CH.sub.3 ; Y=NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2 ; and Z=H, CH.sub.3 or CH.sub.2 CH.sub.3 ; or ##STR3## wherein Y' and Z', independently,=H, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2 or N.sup.+ (CH.sub.3).sub.3 ; Q is N or CH; and salts thereof.

  公开了一种化合物，其化学式为：##STR1## 其中，A独立地等于CH.sub.3或CH.sub.2 CH.sub.3，P=1或2；以及##STR2## 其中，X=NH.sub.2、CH.sub.3或CH.sub.2 CH.sub.3；X'=CH.sub.3或CH.sub.2 CH.sub.3；Y=NH.sub.2、NHCH.sub.3、N(CH.sub.3).sub.2；Z=H、CH.sub.3或CH.sub.2 CH.sub.3；或者##STR3## 其中，Y'和Z'独立地等于H、NH.sub.2、NHCH.sub.3、N(CH.sub.3).sub.2或N.sup.+ (CH.sub.3).sub.3；Q为N或CH；以及其盐。